Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 combination study in advanced solid tumors / advanced NSCLC
CTR20261908Phase 2Active
- Sponsor
- Pfizer
- Start
- Feb 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PF-08634404 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Feb 2026; status: active.
02
Drugs
PF-08634404
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20261908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261908.